1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY |
|||||||||||
|
UNI - EN REPORT No |
4 | / |
2026 |
|
||||||
Date of issue: |
2026-01-08 |
||||||||||
Short name of the issuer |
|||||||||||
SOPHARMA AD |
|||||||||||
Subject |
|||||||||||
Supplement No 1 to the exemption document dated 7 November 2025 |
|||||||||||
Official market - legal basis |
|||||||||||
Art. 56. 1. 2 of Act on Public Offering |
|||||||||||
Unofficial market - legal basis |
|||||||||||
Contents of the report: |
|||||||||||
Sofia, Bulgaria, January 8, 2026 – In reference to current report No. 220/2025 dated 7 November 2025, “Sopharma” AD (SFA: Bulgarian Stock Exchange AD, SPH: Warsaw Stock Exchange) has published a supplement to the exemption document dated 7 November 2025 (the “Exemption Document”)(the “Supplement”). The Supplement has been prepared in order to introduce a correction to the content of the Exemption Document. The Supplement, along with the Exemption Document, are available on the website (https://www.sopharmagroup.com/en/home/investors/prospectuses) of “Sopharma” AD. |
|||||||||||
Annexes |
|||||||||||
File |
Description |
||||||||||
Supplement No 1 to the exemption document dated 7 November 2025 |
|||||||||||
SOPHARMA AD |
|||||||||||||
(fullname of the issuer) |
|||||||||||||
SOPHARMA AD |
Farmaceutyczny (far) |
||||||||||||
(short name of the issuer) |
(sector according to clasification of the WSE in Warsow) |
||||||||||||
1220 |
Sofia |
||||||||||||
(post code) |
(city) |
||||||||||||
IlienskoShosse |
16 | ||||||||||||
(street) |
(number) |
||||||||||||
+359 2 813 42 00 |
+359 2 936 02 86 |
||||||||||||
(phone number) |
(fax) |
||||||||||||
(e-mail) |
(web site) |
||||||||||||
nd |
|||||||||||||
(NIP) |
(REGON) |
||||||||||||
SIGNATURE OF PERSONS REPRESENTING THE COMPANY |
|||||
Date |
Name |
Position / Function |
Signature |
||
2026-01-08 |
Ognian Ivanov Donev |
Executive Director |
|||
